Middle East Pharmaceutical Industries Co (SAU:4016) EBIT: ﷼116.8 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SAU:4016 Middle East Pharmaceutical Industries Co SAU:4016
22 GF Score
Price ﷼60.55
! 3 Warning Signs
View Full Analysis

What is Middle East Pharmaceutical Industries Co EBIT?

Middle East Pharmaceutical Industries Co SAU:4016 +0.92% 22 EBIT is ﷼116.8 Mil as of Mar. 2026. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Middle East Pharmaceutical Industries Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ﷼30.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ﷼116.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Middle East Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Mar. 2026 was 21.53%. Middle East Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Middle East Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.35%.


Middle East Pharmaceutical Industries Co  (SAU:4016) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Middle East Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=124.804 * ( 1 - 7.67% )/( (519.549 + 551.044)/ 2 )
=115.2315332/535.2965
=21.53 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=626.478 - 56.615 - ( 18.819 - max(0, 150.285 - 428.858+18.819))
=551.044

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Middle East Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=122.88/( ( (123.918 + max(289.126, 0)) + (133.873 + max(315.226, 0)) )/ 2 )
=122.88/( ( 413.044 + 449.099 )/ 2 )
=122.88/431.0715
=28.51 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(256.838 + 103.526 + 18.516) - (45.611 + 0 + 44.143)
=289.126

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(286.963 + 101.361 + 21.715) - (56.615 + 0 + 38.198)
=315.226

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Middle East Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=116.83/2183.869
=5.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Middle East Pharmaceutical Industries Co EBIT Related Terms


Middle East Pharmaceutical Industries Co EBIT Historical Data

* Premium members only.

The historical data trend for Middle East Pharmaceutical Industries Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Middle East Pharmaceutical Industries Co EBIT Chart

Middle East Pharmaceutical Industries Co Annual Data
Trend Dec23 Dec24 Dec25
EBIT
78.25 91.03 108.41

Middle East Pharmaceutical Industries Co Quarterly Data
Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.30 28.26 11.01 46.84 30.72

SAU:4016 vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Middle East Pharmaceutical Industries Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Middle East Pharmaceutical Industries Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Middle East Pharmaceutical Industries Co's EV-to-EBIT falls into.


SAU:4016
22GF Score
Middle East Pharmaceutical Industries Co SAU:4016
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Middle East Pharmaceutical Industries Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼116.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ﷼116.8 Mil mean?
Middle East Pharmaceutical Industries Co (SAU:4016) has a EBIT of ﷼116.8 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Middle East Pharmaceutical Industries Co.
Is Middle East Pharmaceutical Industries Co's EBIT too high?
Middle East Pharmaceutical Industries Co's current EBIT is ﷼116.8 Mil. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's EBIT compare to ZTS and UTHR?
Middle East Pharmaceutical Industries Co's EBIT of ﷼116.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Middle East Pharmaceutical Industries Co. Middle East Pharmaceutical Industries Co's current EBIT is ﷼116.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current EBIT of ﷼116.8 Mil. The current EBIT is ﷼116.8 Mil. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current EBIT is ﷼116.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Middle East Pharmaceutical Industries Co Business Description

Address 8146 King Muhammad V, Sulaimaniyah, P.O. Box 4180, Riyadh, SAU, 11491
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score

Get the complete analysis for SAU:4016

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼60.55
Price